Quinn Opportunity Partners LLC Takes $345,000 Position in Progyny, Inc. (NASDAQ:PGNY)

Quinn Opportunity Partners LLC acquired a new stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,000 shares of the company's stock, valued at approximately $345,000.

A number of other hedge funds have also recently bought and sold shares of the company. Signaturefd LLC raised its holdings in shares of Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after purchasing an additional 1,355 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Progyny by 341.4% during the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after purchasing an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after buying an additional 1,526 shares in the last quarter. Caitlin John LLC raised its position in Progyny by 2,974.8% during the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after acquiring an additional 3,183 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in Progyny in the fourth quarter valued at approximately $74,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have commented on PGNY. Canaccord Genuity Group increased their target price on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research report on Friday, February 28th. JPMorgan Chase & Co. upped their target price on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research report on Tuesday, January 28th. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective on the stock in a research note on Monday, March 31st. Finally, Bank of America raised their price objective on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Progyny presently has a consensus rating of "Hold" and a consensus target price of $23.64.

Progyny Stock Performance

NASDAQ PGNY traded down $0.14 on Thursday, reaching $21.26. The company had a trading volume of 425,808 shares, compared to its average volume of 1,792,499. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of 36.66, a price-to-earnings-growth ratio of 2.39 and a beta of 1.33. The company's fifty day moving average is $21.98 and its 200-day moving average is $18.77. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $33.84.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.